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Introduction
Aortic stenosis(AS) is the most prevalent valvular disease
(incidence 2% over 65years). Valvular area decreases
0.3m/s/y, transvalvular gradient (7mmHg/y) and blood
speed(0.3m/s/y) increases with age. AS treatment can be
medical or surgical:heart valve replacement surgery or
percutaneous placement of an aortic endoprothesis
(TAVR) in patients with high perioperative risk. TAVR is
beneficial and improves their expectative and quality of
life (QOL) compared with medical treatment.
Objectives
To describe the incidence of complications of TAVR
and to determine the validity of our protocol.
Methods
Descriptive observational study during 2012-2014 of
TAVR complications with Corevalve device at Burgos
University Hospital. We analyzed epidemiological charac-
teristics, comorbidities, and complications. We applied the
actual protocol in all patients, which consist in femoral
artery access, provisional pacemaker(PM), antibiotic and
high digestive bleeding prophylaxis. During TAVR patients
are superficially sedated and ventilated with self-expanded
balloon. Afterwards patients are admitted to ICU continu-
ing hemodynamic monitoring, neurologic vigilance, and
vascular access care hourly. Systematically and detailed
echocardiography is made. Double antiaggregation and
haemoglobin are optimized. Seriated blood tests are taken.
If there is no atrioventricular block(AVB) after 24 hours
the PM is removed.
Results
We analyze 22 patients with severe AS undergoing
TAVR, with good QOL and comorbidities similar to
those described in table 1. Mean age 84.2years (SD
5.063), 68.2% women. Median APACHE II score 13 and
mean Euroscore 17.
Complications in ICU (Table 2): blood transfusion
63.7%, acute kidney injury(AKI) 31.8%, AVB 27.3%
(definitive PM); stroke(9.1%), and absence of infection.
Three patients had a cardiac arrest during the proce-
dure (TAVR was not implanted) and only one of them
survived. TAVR migration occurred once and required
recolocation.
Conclusions
TAVR using our protocol is a safe technique but not free
of complications in patients with high surgical risk. Most
of these complications were transfusion requirements,
conduction system abnormalities, and AKI resolved at
discharge. No nosocomial infections or need of pro-
longed mechanical ventilation was observed. These
results are comparable to the experience in other centers,
so we validate our protocol.
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Table 2. Complications after TAVR implantation
Residual Aortic Regurgitation 18.2%
Cardiac Arrest 18.2%




ICU Stay 2.7 (SD 0.3)
Hospital Stay 11.23 (SD 1.36)
30 days Mortality 13.6%
1 year Mortality 13.6%
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